Eiger BioPharmaceuticals to Present at the 2022 Ladenburg Thalmann Healthcare Conference
Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR) announced that its President and CEO, David Cory, will present at the 2022 Ladenburg Thalmann Healthcare Conference on September 29, 2022, at 1:00 PM ET in New York City. The company focuses on innovative therapies for hepatitis delta virus (HDV) and other serious diseases, with two HDV therapies in Phase 3 trials. A live webcast of the presentation will be available on their website, along with a replay for 90 days. Eiger's HDV programs have received FDA Breakthrough Therapy designation.
- None.
- None.
PALO ALTO, Calif., Sept. 22, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today announced that David Cory, President and CEO, will present a company overview at the 2022 Ladenburg Thalmann Healthcare Conference on Thursday, September 29, 2022 at 1:00 PM ET in New York City. Eiger will also host one-on-one meetings with investors at the conference.
A live webcast of the presentation will be available on the Investors section of the Eiger BioPharmaceuticals website at www.eigerbio.com, and a replay will be available on the website for at least 90 days.
Eiger is a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases. The Eiger HDV platform includes two first-in-class therapies in Phase 3 that target critical host processes involved in viral replication. All five Eiger rare disease programs have been granted FDA Breakthrough Therapy designation: lonafarnib and peginterferon lambda for HDV, Zokinvy for progeria, and avexitide for both congenital hyperinsulinism and post-bariatric hypoglycemia.
For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.
Contacts
Investors:
Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com
Media:
Sarah Mathieson
SVP, Corporate Affairs
smathieson@eigerbio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-to-present-at-the-2022-ladenburg-thalmann-healthcare-conference-301630711.html
SOURCE Eiger BioPharmaceuticals, Inc.
FAQ
When will Eiger BioPharmaceuticals present at the Ladenburg Thalmann Healthcare Conference?
Who is the CEO of Eiger BioPharmaceuticals?
What focus does Eiger BioPharmaceuticals have in its drug development?
Where can I find the live webcast of Eiger's presentation?